Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

667 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Obesity is linked to disease severity in moderate to severe atopic dermatitis-Data from the prospective observational TREATgermany registry.
Traidl S, Hollstein MM, Kroeger N, Fischer S, Heratizadeh A, Heinrich L, Kind B, Siegels D, Abraham S, Schäfer T, Augustin M, Harder I, Pinter A, Schäkel K, Wollenberg A, Ertner K, Ramaker-Brunke J, Bong A, Quist S, Gorriahn-Maiterth H, Schenck F, Sticherling M, Effendy I, Schwarz B, Handrick C, Asmussen A, Weidinger S, Schmitt J, Werfel T; TREATgermany Study Group. Traidl S, et al. Among authors: pinter a. J Eur Acad Dermatol Venereol. 2024 Apr 25. doi: 10.1111/jdv.20042. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 38661511
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NM, Pirozzi G, Akinlade B, Staudinger H, Mastey V, Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M; SOLO 1 and SOLO 2 Investigators. Simpson EL, et al. N Engl J Med. 2016 Dec 15;375(24):2335-2348. doi: 10.1056/NEJMoa1610020. Epub 2016 Sep 30. N Engl J Med. 2016. PMID: 27690741 Free article. Clinical Trial.
Topische Therapie bei Psoriasis vulgaris - ein Behandlungspfad.
Körber A, Wilsmann-Theis D, Augustin M, von Kiedrowski R, Mrowietz U, Rosenbach T, Meller S, Pinter A, Sticherling M, Gerdes S; PsoNet Förderverein. Körber A, et al. Among authors: pinter a. J Dtsch Dermatol Ges. 2019 May;17 Suppl 4:3-14. doi: 10.1111/ddg.13810. Epub 2019 Mar 18. J Dtsch Dermatol Ges. 2019. PMID: 30883011
Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus.
Silverberg JI, Pinter A, Pulka G, Poulin Y, Bouaziz JD, Wollenberg A, Murrell DF, Alexis A, Lindsey L, Ahmad F, Piketty C, Clucas A. Silverberg JI, et al. Among authors: pinter a. J Allergy Clin Immunol. 2020 Jan;145(1):173-182. doi: 10.1016/j.jaci.2019.08.013. Epub 2019 Aug 23. J Allergy Clin Immunol. 2020. PMID: 31449914 Free article. Clinical Trial.
A phase 4, randomized, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE).
Pinter A, Hoffmann M, Reich K, Augustin M, Kaplan K, Gudjónsdóttir SD, Delvin T, Mrowietz U; CHANGE investigator group. Pinter A, et al. J Eur Acad Dermatol Venereol. 2021 Mar;35(3):701-711. doi: 10.1111/jdv.16932. Epub 2020 Dec 23. J Eur Acad Dermatol Venereol. 2021. PMID: 32939860 Clinical Trial.
Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment.
Leutz A, Pinter A, Thaçi D, Augustin M, Schuster C, Fotiou K, Hundemer HP, Saure D, Mrowietz U, Reich K. Leutz A, et al. Among authors: pinter a. Br J Dermatol. 2021 Mar;184(3):548-550. doi: 10.1111/bjd.19558. Epub 2020 Nov 10. Br J Dermatol. 2021. PMID: 32940343 No abstract available.
Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial.
Thaçi D, Soliman AM, Eyerich K, Pinter A, Sebastian M, Unnebrink K, Rubant S, Williams DA, Weisenseel P. Thaçi D, et al. Among authors: pinter a. J Eur Acad Dermatol Venereol. 2021 Aug;35(8):1686-1691. doi: 10.1111/jdv.17109. Epub 2021 Jul 12. J Eur Acad Dermatol Venereol. 2021. PMID: 33428281 Clinical Trial.
Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study.
Mrowietz U, Burden AD, Pinter A, Reich K, Schäkel K, Baum P, Datsenko Y, Deng H, Padula SJ, Thoma C, Bissonnette R. Mrowietz U, et al. Among authors: pinter a. Dermatol Ther (Heidelb). 2021 Apr;11(2):571-585. doi: 10.1007/s13555-021-00504-0. Epub 2021 Mar 4. Dermatol Ther (Heidelb). 2021. PMID: 33661508 Free PMC article.
Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B study.
Silverberg JI, Pinter A, Alavi A, Lynde C, Bouaziz JD, Wollenberg A, Murrell DF, Alpizar S, Laquer V, Chaouche K, Ahmad F, Armstrong JM, Piketty C. Silverberg JI, et al. Among authors: pinter a. J Eur Acad Dermatol Venereol. 2021 Jul;35(7):1562-1568. doi: 10.1111/jdv.17218. Epub 2021 Apr 1. J Eur Acad Dermatol Venereol. 2021. PMID: 33711179 Clinical Trial.
IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE).
Eyerich K, Weisenseel P, Pinter A, Schäkel K, Asadullah K, Wegner S, Muñoz-Elias EJ, Bartz H, Taut FJH, Reich K. Eyerich K, et al. Among authors: pinter a. BMJ Open. 2021 Sep 13;11(9):e049822. doi: 10.1136/bmjopen-2021-049822. BMJ Open. 2021. PMID: 34518264 Free PMC article.
667 results